Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

Philipp du Cros

20 ta ish

University College London

AkademScholarda batafsil koʻrsatkichlar

  1. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011

    Dilrabo Ulmasova, G Uzakova, M N Tillyashayhov +17

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEurosurveillance201315 iqtibos
    ABI

  2. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

    Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos
    ABI

  3. Where there is hope: a qualitative study examining patients’ adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    Shona Horter, Beverley Stringer, Jane Greig +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Infectious Diseases20164 iqtibos
    ABI

  4. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses

    Faiz Ahmad Khan, M Salim, Philipp du Cros +9

    Sharh maqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20174 iqtibos
    ABI

  5. Risk Factors Associated with Default from Multi- and Extensively Drug-Resistant Tuberculosis Treatment, Uzbekistan: A Retrospective Cohort Analysis

    Maeve K. Lalor, Jane Greig, Sholpan Allamuratova +6

    MaqolaOchiq kirish20134 iqtibos
    ABI

  6. Principles for designing future regimens for multidrug-resistant tuberculosis

    Grania Brigden, Bern-Thomas Nyang’wa, Philipp du Cros +9

    MaqolaOchiq kirish20133 iqtibos
    ABI

  7. Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan

    James M. Trauer, Jay Achar, Nargiza Parpieva +7

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyBMC Medicine20163 iqtibos
    ABI

  8. ‘They prefer hidden treatment': anti-tuberculosis drug-taking practices and drug regulation in Karakalpakstan

    Beverley Stringer, Karen Lowton, Mirzagaleb N. Tillashaikhov +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20162 iqtibos
    ABI

  9. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

    Catherine Berry, Philipp du Cros, Katherine Fielding +7

    MaqolaOchiq kirish20222 iqtibos
    ABI

  10. Research Protocol - Effectiveness of a simplified short regimen for Multidrug Resistant Tuberculosis treatment in Karakalpakstan, Uzbekistan

    Philipp du Cros, Khamraev Atadjan, Mirzagalib Tillashaikhov +19

    Maqola20142 iqtibos
    ABI

  11. Revised Definitions of Multidrug-Resistant Tuberculosis Treatment Outcomes: Closer to the Reality?

    Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

    BoshqaTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20151 iqtibos
    ABI

  12. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

    Johanna Kuhlin, Chris Smith, Atadjan Khaemraev +8

    MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20181 iqtibos
    ABI

  13. Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

    S.K. Abidi, Jay Achar, M.M. Assao Neino +34

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyEuropean Respiratory Journal20191 iqtibos
    ABI

  14. Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

    Philipp du Cros, Atadjan Khamraev, Zinaida Tigay +15

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyERJ Open Research20201 iqtibos
    ABI

  15. Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

    Maryline Bonnet, Mathieu Bastard, Philipp du Cros +7

    MaqolaTuberculosis Research and EpidemiologyEuropean Respiratory Journal20130 iqtibos
    ABI

  16. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

    M. Bonnet, Mathieu Bastard, Philipp du Cros +9

    MaqolaTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20150 iqtibos
    ABI

  17. Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen

    Jay Achar, Catherine Berry, Krzysztof Herboczek +7

    BoshqaOchiq kirishTuberculosis Research and EpidemiologyEmerging infectious diseases20150 iqtibos
    ABI

  18. Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

    Mathieu Bastard, Maryline Bonnet, Philipp du Cros +9

    BoshqaTuberculosis Research and EpidemiologyAmerican Journal of Respiratory and Critical Care Medicine20150 iqtibos
    ABI

  19. Early cardiac safety of the 9-11 month Short course regimen for MDR-TB treatment

    Catherine Berry, James McMahon, Bern-Thomas Nyang’wa +5

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyInternational Journal of Infectious Diseases20160 iqtibos
    ABI

  20. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

    Mathieu Bastard, Elisabeth Sánchez-Padilla, Philipp du Cros +12

    MaqolaOchiq kirishTuberculosis Research and EpidemiologyPLoS ONE20180 iqtibos
    ABI